Believed to be the only such bacterial virulence protein- identification technology in the world, Antex scientists will use VEP to accelerate the development of new vaccines and antibiotics that will prevent infectious diseases and kill bacteria. Efficient disease related protein identification offers considerable competitive advantage by speeding up drug and vaccine discovery. There is a great deal of excitement about this innovative technology. Ultimately, VEP will lead Antex to new antibiotic and vaccine discoveries that will fight infectious diseases, such as Strep and Staph infections that are becoming increasingly resistant to antibiotics now available. The net result is an extremely high identification rate of proteins that cause disease.
Current antibiotics work against just a few disease-related proteins in the body.
VEP should yield a quantum leap revealing many new targets as well as antigens for use as vaccines. NST technology works by identifying the particular signals, natural chemicals and other in vivo conditions that transduce bacteria and enhance the expression of specific virulence properties. NST-grown microbes are 'virulence enhanced,' and therefore, more clinically relevant bacteria. Antex Biologics is a biopharmaceutical company committed to developing and marketing new products to prevent and treat infections and related diseases. The Company has three vaccine products, discovered using these technologies, in clinical development.